254 related articles for article (PubMed ID: 34740514)
1. Variant transthyretin amyloidosis (ATTRv) polyneuropathy in Greece: a broad overview with a focus on non-endemic unexplored regions of the country.
Koutsis G; Kastritis E; Kontogeorgiou Z; Kartanou C; Kokotis P; Rentzos M; Breza M; Kleopa KA; Christodoulou K; Oikonomou E; Anastasakis A; Angelidakis P; Sarmas I; Kargiotis O; Tzagournissakis M; Zaganas I; Foukarakis E; Sachpekidis V; Papathoma A; Panas M; Stefanis L; Dimopoulos MA; Karadima G
Neuromuscul Disord; 2021 Dec; 31(12):1251-1258. PubMed ID: 34740514
[TBL] [Abstract][Full Text] [Related]
2. Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry.
Pinto MV; Pinto LF; Dias M; Rosa RS; Mundayat R; Pedrosa RC; Waddington-Cruz M
J Neurol Sci; 2019 Aug; 403():1-6. PubMed ID: 31163298
[TBL] [Abstract][Full Text] [Related]
3. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
4. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
7. Variant Transthyretin Amyloidosis (ATTRv) in Hungary: First Data on Epidemiology and Clinical Features.
Pozsonyi Z; Peskó G; Takács H; Csuka D; Nagy V; Szilágyi Á; Hategan L; Muk B; Csányi B; Nyolczas N; Dézsi L; Molnár JM; Csillik A; Révész K; Iványi B; Szabó F; Birtalan K; Masszi T; Arányi Z; Sepp R
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440326
[TBL] [Abstract][Full Text] [Related]
8. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes in non-endemic hereditary transthyretin amyloidosis with polyneuropathy: a 20-year German single-referral centre experience.
Ungerer MN; Hund E; Purrucker JC; Huber L; Kimmich C; Aus dem Siepen F; Hein S; Kristen AV; Hinderhofer K; Kollmer J; Schönland S; Hegenbart U; Weiler M
Amyloid; 2021 Jun; 28(2):91-99. PubMed ID: 33283548
[TBL] [Abstract][Full Text] [Related]
10. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS).
Gentile L; Diemberger I; Plante-Bordeneuve V; Mazzeo A; Dori A; Luigetti M; Di Paolantonio A; Dispenzieri A; Grogan M; Waddington Cruz M; Adams D; Inamo J; Kristen AV; Lino Cirami C; Chapman D; Gupta P; Glass O; Amass L
PLoS One; 2024; 19(1):e0292435. PubMed ID: 38241252
[TBL] [Abstract][Full Text] [Related]
12. Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis.
Alves-Ferreira M; Azevedo A; Coelho T; Santos D; Sequeiros J; Alonso I; Sousa A; Lemos C
Amyloid; 2021 Jun; 28(2):100-106. PubMed ID: 33461327
[TBL] [Abstract][Full Text] [Related]
13. Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore.
Chen Z; Koh JS; Saini M; Tay KSS; Jayne Tan Y; Chai JYH; Fam SR; Juraidah AR; Lim PK; Ng ASL; Prasad K; Tan CB; Umapathi T; Verma KK; Yong MH; Yu C; Ng PS
J Neuromuscul Dis; 2021; 8(4):723-733. PubMed ID: 34024775
[TBL] [Abstract][Full Text] [Related]
14. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
16. Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan.
Matsushima M; Tarisawa M; Nomura T; Oshima Y; Yoshino M; Shibata Y; Wakita M; Shirai S; Iwata I; Yaguchi H; Yabe I
Intern Med; 2023 Jun; 62(11):1599-1602. PubMed ID: 36261369
[TBL] [Abstract][Full Text] [Related]
17. Characterization and natural history of different phenotypes in hereditary transthyretin amyloidosis: 40-year experience at a single Italian referral centre.
Caponetti AG; Sguazzotti M; Accietto A; Saturi G; Ponziani A; Giovannetti A; Massa P; Ruotolo I; Sena G; Zaccaro A; Parisi V; Bonfiglioli R; Guaraldi P; Gagliardi C; Cortelli P; Galie N; Biagini E; Longhi S
Eur J Prev Cardiol; 2024 May; 31(7):866-876. PubMed ID: 38204330
[TBL] [Abstract][Full Text] [Related]
18. Transthyretin Variant Amyloidosis with a TTR A97D (p.A117D) Mutation Manifesting Remarkable Asymmetric Neuropathy.
Ikeda K; Yamamoto D; Usui K; Takeuchi H; Oka N; Katoh N; Yazaki M; Kametani F; Nishino I; Hisahara S
Intern Med; 2023 Aug; 62(15):2261-2266. PubMed ID: 36543209
[TBL] [Abstract][Full Text] [Related]
19. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
[TBL] [Abstract][Full Text] [Related]
20. A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.
Olsson M; Norgren N; Obayashi K; Plante-Bordeneuve V; Suhr OB; Cederquist K; Jonasson J
BMC Med Genet; 2010 Sep; 11():130. PubMed ID: 20840742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
